[1] Studdert DM, Hall MA, Mello MM. Partitioning the curve - interstate travel restrictions during the Covid-19 pandemic. N Engl J Med 2020; published online Aug 5. DOI: 10.1056/NEJMp2024274.
[2] Peng M. Outbreak of COVID-19: An emerging global pandemic threat. Biomed Pharmacother 2020;129:110499.
[3] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-78.
[4] Srivastava S, Verma S, Kamthania M, et al. Structural basis for designing multiepitope vaccines against COVID-19 infection: in silico vaccine design and validation. JMIR Bioinform Biotech 2020;1:e19371.
[5] Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324:1-11.
[6] Shanmugaraj B, Siriwattananon K, Wangkanont K, et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020;38:10-18.
[7] Kabir MT, Uddin MS, Hossain MF, et al. nCOVID-19 pandemic: from molecular pathogenesis to potential investigational therapeutics. Front Cell Dev Biol 2020;8:616.
[8] Schönrich G, Raftery MJ, Samstag Y. Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Adv Biol Regul 2020;77:100741.
[9] Bal A, Agrawal R, Vaideeswar P, et al. COVID-19: an up-to-date review - from morphology to pathogenesis. Indian J Pathol Microbiol 2020;63:358-66.
[10] Shenoy S. Coronavirus (Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality. Inflamm Res 2020; published online Aug 7. DOI: 10.1007/s00011-020-01389-z.
[11] Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110-8.
[12] Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev 2020;53:38-42.
[13] Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol 2020; published online May 20. DOI: 10.1099/jgv.0.001439.
[14] Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26:845-8.
[15] Peterhoff D, Glück V, Vogel M, et al. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection 2020;1-8.
[16] Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020; published online Feb 27. DOI:10.1002/jmv.25727
[17] Bryan A, Pepper G, Wener MH, et al. Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in boise, idaho. J Clin Microbiol 2020;58:e00941-20.
[18] Theel ES, Slev P, Wheeler S, et al. The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol 2020;58:e00797-20.
[19] Sordillo PP, Helson L. Curcumin suppression of cytokine release and cytokine storm. A potential therapy for patients with Ebola and other severe viral infections. In Vivo 2015;29:1-4.
[20] Liu YP, Li GM, He J, et al. Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study. Ann Transl Med 2020;8:635.
[21] Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 2020;9:1123-30.
[22] Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 2020;221:1762-9.
[23] Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71:762-8.
[24] Ni M, Tian FB, Xiang DD, et al. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19. J Med Virol 2020; published online May 29. DOI: 10.1002/jmv.26070.
[25] Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020;55:102763.
[26] Jiang M, Guo Y, Luo Q, et al. T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of Coronavirus disease 2019. J Infect Dis 2020;222:198-202.